新型非典型抗精神病药临床应用评价  

Evaluation of new atypical antipsychotics in clinical application

作　　者：翟金国[1] 赵靖平[1] 房茂胜[1] 

机构地区：[1]中南大学湘雅二医院精神卫生研究所,湖南长沙410011

出　　处：《中国新药与临床杂志》2006年第4期296-301,共6页Chinese Journal of New Drugs and Clinical Remedies

基　　金：国家"十五"科技攻关项目(2004BA720A22)

摘　　要：目前非典型抗精神病药应用越来越广泛,有逐渐取代典型抗精神病药的趋势,不但用于精神分裂症的治疗,而且作为心境稳定剂治疗情感障碍。本文对非典型抗精神病药的概念、治疗阴性症状和较少锥体外系不良反应的机制、在精神分裂症和情感障碍治疗中的临床应用评价等文献进行综述,重点讨论奥氮平、利司哌酮、喹硫平、阿立哌唑、齐哌西酮、氨磺必利和哌罗匹隆。Atypical antipsychotics（AAP） are utilized extensively now a days to treat not only schizophrenia but also for mood disorders as mood stabilizer because of the effect and the safety for positive and negative symptoms of schizophrenia and the affective symptoms of affective disorders especially bipolar disorders. A review of recent literatures concerned about the concept and application of AAP such as olanzapine,risperidone, quetiapine,aripiprazole,ziprasidone,amisulpiride and perospirone as well for schizophrenia and mood disorders are evaluated.

关 键 词：奥氮平 利司哌酮 喹硫平 阿立哌唑 齐哌西酮 哌罗匹隆 氨磺必利 非典型抗精神病药 

分 类 号：R971.4[医药卫生—药品]